세계의 포스포이노시티드 3 키나아제(PI3K) 억제제 시장 보고서(2025년)

Phosphoinositide 3-Kinase (PI3K) inhibitors are a class of drugs that target the PI3K enzyme, which plays a crucial role in regulating cell growth, survival, and metabolism. These inhibitors help control abnormal cell division and tumor growth, making them effective in treating various cancers, including breast cancer, leukemia, and lymphoma. PI3K inhibitors work by blocking signaling pathways that promote the survival and proliferation of cancer cells, ultimately slowing down or halting tumor progression.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of PI3K inhibitors include isoform-selective inhibitors, pan-PI3K inhibitors, dual PI3K or mechanistic target of rapamycin (mTOR) inhibitors, and novel targeted inhibitors. Isoform-selective inhibitors are specialized compounds that selectively target and inhibit specific isoforms of an enzyme or protein, reducing off-target effects and improving therapeutic precision. These inhibitors are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are primarily used in cancer treatment, metabolic disorders, autoimmune diseases, and neurological disorders, with end-users including hospitals, research institutes, pharmaceutical companies, and contract research organizations (CROs).

The phosphoinositide 3-kinase (PI3K) inhibitors market research report is one of a series of new reports from The Business Research Company that provides phosphoinositide 3-kinase (PI3K) inhibitors market statistics, including phosphoinositide 3-kinase (PI3K) inhibitors industry global market size, regional shares, competitors with a phosphoinositide 3-kinase (PI3K) inhibitors market share, detailed phosphoinositide 3-kinase (PI3K) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the phosphoinositide 3-kinase (PI3K) inhibitors industry. This phosphoinositide 3-kinase (PI3K) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The phosphoinositide 3-kinase (PI3K) inhibitors market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.57 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of cancer, growing research on targeted therapies, regulatory approvals for first-generation PI3K inhibitors, rising healthcare expenditure, and the expansion of clinical trials for hematologic malignancies.

The phosphoinositide 3-kinase (PI3K) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth projected for the forecast period can be attributed to several factors, including the increasing demand for combination therapies, the emergence of next-generation PI3K inhibitors with improved safety profiles, rising investment in cancer research and development, the expansion of indications beyond oncology, and the growing adoption of biomarkers for patient selection. Key trends during this period include a shift toward dual and pan-isoform PI3K inhibitors, a growing preference for oral formulations over intravenous options, a greater focus on overcoming resistance mechanisms, the increasing integration of artificial intelligence in drug discovery, and the expanding role of PI3K inhibitors in immunotherapy combinations.

The increasing prevalence of cancer and autoimmune diseases is expected to significantly drive the growth of the phosphoinositide 3-kinase (PI3K) inhibitors market in the coming years. Cancer, which involves uncontrolled cell growth, and autoimmune diseases, where the immune system mistakenly attacks the body's own tissues, are both on the rise. This is largely due to genetic predispositions, accumulated genetic mutations, and immune system dysregulation over time. PI3K inhibitors are essential in addressing the rising incidence of these diseases by targeting abnormal PI3K signaling pathways, which are implicated in tumor progression and immune system dysfunction. These inhibitors offer precision medicine approaches that improve treatment efficacy and patient outcomes. For example, the National Cancer Institute projected that the number of cancer survivors in the U.S. would rise from 18.1 million in 2022 to 22.5 million by 2032. This indicates a growing demand for treatments, including PI3K inhibitors, to manage cancer and autoimmune diseases, driving the market forward.

Leading companies in the PI3K inhibitors market are making significant strides in developing targeted therapies, including PI3K delta inhibitor treatments, to address diseases linked to dysregulated PI3K signaling. PI3K delta inhibitors specifically target the PI3K delta enzyme, which plays a crucial role in immune cell signaling. By inhibiting this enzyme, these therapies can help reduce inflammation, autoimmune responses, and certain blood cancers. For instance, in March 2023, the U.S. Food and Drug Administration (FDA) approved Joenja (leniolisib), the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. This approval marked a significant milestone in personalized medicine, offering a precision treatment approach to address immune dysfunction caused by genetic mutations in the PIK3CD or PIK3R1 genes. The approval of Joenja demonstrates how PI3K inhibitors are being used not just in oncology but in treating rare immunological disorders, underscoring the shift towards more targeted, individualized therapies in the market.

In October 2024, OnKure Therapeutics, a U.S.-based biopharmaceutical company, merged with Reneo Pharmaceuticals to create a combined entity focused on advancing mutant-selective PI3Ka inhibitors for cancer treatment. This merger, which involved a substantial financial commitment, aims to accelerate the development of precision medicines that specifically target mutant PI3Ka enzymes implicated in various cancers. PI3Ka inhibitors, which selectively target mutant forms of the PI3K alpha enzyme, are being explored as a potential treatment for cancers that have developed resistance to traditional therapies. The merger strengthens both companies' positions in oncology and accelerates the clinical development of novel therapies, potentially transforming cancer treatment paradigms and expanding the PI3K inhibitors market.

Major players in the phosphoinositide 3-kinase (pi3k) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology.

North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphoinositide 3-kinase (PI3K) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphoinositide 3-kinase (PI3K) inhibitors market consists of sales of oral formulations, intravenous injections, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phosphoinositide 3-Kinase (PI3K) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on phosphoinositide 3-kinase (pi3k) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for phosphoinositide 3-kinase (pi3k) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phosphoinositide 3-kinase (pi3k) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Inhibitor: Isoform Selective Inhibitors; Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors; Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors; Novel Targeted Inhibitors
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channel
• 3) By Application Areas: Cancer Treatment; Metabolic Disorders; Autoimmune Diseases; Neurological Disorders
• 4) By End User: Hospitals; Research Institutes; Pharmaceutical Companies; Contract Research Organizations (CROs)
• Subsegments:
• 1) By Isoform Selective Inhibitors: Phosphoinositide 3-Kinase Alpha (PI3Ka); Phosphoinositide 3-Kinase Beta (PI3KB); Phosphoinositide 3-Kinase Delta (PI3Kδ); Phosphoinositide 3-Kinase Gamma (PI3KY)
• 2) By Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors: Class I Phosphoinositide 3-Kinase (PI3K); Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K); Phosphoinositide 3-Kinase Kinase Domain
• 3) By Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target of Rapamycin (mTOR) Inhibitors: Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition; Adenosine Triphosphate-Competitive Dual Inhibitors; Allosteric Dual Inhibitors
• 4) By Novel Targeted Inhibitors: Next-Generation Phosphoinositide 3-Kinase; Targeting Mutant Phosphoinositide 3-Kinase Isoforms; Autophagy Modulators; Checkpoint Inhibitors; Combination Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Characteristics

3. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Trends And Strategies

4. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate Analysis
• 5.4. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Total Addressable Market (TAM)

6. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation

• 6.1. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Isoform Selective Inhibitors
• Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors
• Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors
• Novel Targeted Inhibitors
• 6.2. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channel
• 6.3. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment
• Metabolic Disorders
• Autoimmune Diseases
• Neurological Disorders
• 6.4. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• 6.5. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Sub-Segmentation Of Isoform Selective Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phosphoinositide 3-Kinase Alpha (PI3Ka)
• Phosphoinositide 3-Kinase Beta (PI3KB)
• Phosphoinositide 3-Kinase Delta (PI3Kδ)
• Phosphoinositide 3-Kinase Gamma (PI3KY)
• 6.6. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Sub-Segmentation Of Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Class I Phosphoinositide 3-Kinase (PI3K)
• Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K)
• Phosphoinositide 3-Kinase Kinase Domain
• 6.7. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Sub-Segmentation Of Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition
• Adenosine Triphosphate-Competitive Dual Inhibitors
• Allosteric Dual Inhibitors
• 6.8. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Sub-Segmentation Of Novel Targeted Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Phosphoinositide 3-Kinase
• Targeting Mutant Phosphoinositide 3-Kinase Isoforms
• Autophagy Modulators
• Checkpoint Inhibitors
• Combination Therapies

7. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Regional And Country Analysis

• 7.1. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 8.1. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 9.1. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 9.2. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 10.1. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 11.1. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 11.2. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 12.1. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 13.1. Indonesia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 14.1. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 14.2. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 15.1. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 15.2. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 16.1. UK Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 17.1. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 18.1. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 19.1. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 20.1. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 21.1. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 21.2. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 22.1. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 23.1. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 23.2. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 24.1. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 24.2. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 25.1. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 25.2. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 26.1. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 26.2. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 27.1. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 28.1. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 28.2. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

• 29.1. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Overview
• 29.2. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market, Segmentation By Application Areas, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Competitive Landscape
• 30.2. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol Myers Squibb
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline (GSK) Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences
• 31.9. Boehringer Ingelheim
• 31.10. Genentech Inc.
• 31.11. Incyte Corporation
• 31.12. Exelixis
• 31.13. Kura Oncology
• 31.14. TG Therapeutics Inc.
• 31.15. Verastem Oncology

32. Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

34. Recent Developments In The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

35. Phosphoinositide 3-Kinase (PI3K) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34926_Phosphoinositide_3_Kinase_PI3K_Inhibitors_GMR_2025